Oct 27 (Reuters) - Organon said on Monday CEO

Kevin Ali will resign from his role, after an internal

investigation into sales of its Nexplanon contraceptive implant

to wholesalers pointed to "improper" practices.

An audit committee found certain U.S. wholesalers were

asked to purchase more Nexplanon than needed at the end of

several quarters between 2022 and 2025.

"While the findings to date do not necessitate a

restatement or revision to any previously issued financial

statements, the company is taking remedial actions to improve

its financial controls and address any material weaknesses," it

said in a statement.

Ali will be replaced by Joseph Morrissey, currently

executive vice president and head of manufacturing and supply,

as CEO on an interim basis effective immediately.

The former chief executive has agreed he will not be

entitled to severance or equity-related retirement benefits in

connection with his resignation.